New hope for tough cancers: first human test of targeted drug begins
Disease control
Ongoing
This is an early-stage study to test a new oral drug called TPX-0022 (elzovantinib) in adults with advanced or spreading cancers that have specific changes in a gene called MET. The main goals are to find a safe dose, see how the body processes the drug, and get a first look at w…
Phase: PHASE1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC